AN2 10-Q: Q3 Loss Narrows to $8.0M, $80.2M Cash, Material Weaknesses Persist
ANTX has more than doubled off its 52-week low of $1.
Summary
AN2's Q3 10-Q confirms the $8.0M quarterly loss and $80.2M cash position already reported this morning, and states that previously identified material weaknesses in internal control over financial reporting continue as of September 30, 2026.
Key Events · Earnings and Guidance · ANTX
-
Q3 Loss Narrows to $8.0M
Net loss was $7.957M, or $0.17 per share, versus $9.353M, or $0.31 per share, in Q3 2025; R&D fell to $5.724M from $7.000M.
-
Cash of $80.2M, Runway Into 2029
Cash, cash equivalents and investments totaled $80.2M at September 30, 2026; nine-month operating cash burn was $25.2M against a $26.2M net loss.
-
Material Weaknesses Persist
Management concluded disclosure controls were not effective as of September 30, 2026 because previously identified material weaknesses in internal control over financial reporting continue to exist, with no remediation timeline given.
-
ATM Leaves $71.8M of Headroom
AN2 sold 1,692,768 shares under the 2026 ATM for $8.0M net in the first nine months and may still sell up to $71.8M under the Jefferies agreement; 8,741,493 pre-funded warrants remain unexercised.
Analysis · ANTX · Life Sciences
The headline numbers were already out in this morning's 8-K, so the P&L itself is not new. What the 10-Q adds is the audited-style detail behind them: cash and investments of $80.2M at September 30, 2026, a $26.2M nine-month loss, and an explicit statement that the previously identified material weaknesses in internal control over financial reporting continue to exist as of September 30, 2026 with no remediation timeline. It also confirms the balance-sheet moves that fund the pipeline — $37.2M net from the March 2026 private placement and $8.0M net from the ATM — leaving $71.8M still available to sell under the Jefferies agreement, an overhang on top of 8.7M pre-funded warrants. For a clinical-stage company burning roughly $25M of operating cash over nine months, the runway statement is the thing that matters; the control weaknesses are the recurring governance blemish.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANTX was trading at $4.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $150.9M. The 52-week trading range was $1.00 to $7.19. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.